Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Clade Therapeutics is raising $87,142,085.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chad Cowan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Clade Therapeutics
Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.

To learn more about Clade Therapeutics, visit http://cladetx.com/

Contact:
Chad Cowan, Chief Executive Officer
415-886-7710

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved